Abstract
Background: The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied.
Methods: We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations.
Results: Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices.
Conclusion: Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.
Keywords: COVID-19; CoronaVac; Fingolimod; Multiple sclerosis; SARS-COV-2; Vaccination.
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, multiple sclerosis, CoronaVac, fingolimod, 【초록키워드】 Treatment, Vaccine, coronavirus, antibody, anti-SARS-CoV-2, ELISA, Prevalence, sera, inactivated, spike IgG, Vaccinations, humoral, Support, acute respiratory syndrome, healthy individuals, participant, Multiple, significantly lower, recruited, were measured, impairing, Person, 【제목키워드】 Antibody Response, Inactivated vaccine, SARS-CoV-2 spike protein, fingolimod, impair,